Condition (MeSH)
AIDS Dementia Complex
ClinicalTrials.gov lists 41 trials for AIDS Dementia Complex or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 7.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
41 of the 41 trials are tagged with AIDS Dementia Complex itself; the rest are tagged with a narrower condition beneath it.
When did AIDS Dementia Complex trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 2 |
| 2018 | 1 |
| 2017 | 4 |
| 2016 | 1 |
| 2015 | 5 |
| 2014 | 2 |
| 2013 | 1 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are AIDS Dementia Complex trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 3 |
| Phase 2 | 7 |
| Phase 2/3 | 2 |
| Phase 3 | 5 |
| Phase 4 | 5 |
| Not applicable | 8 |
| Observational | 7 |
How many AIDS Dementia Complex trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 29 |
| Terminated | 6 |
| Withdrawn | 1 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most AIDS Dementia Complex trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 7 |
| Centaur Pharmaceuticals | 2 |
| Glaxo Wellcome | 2 |
| National Institute of Mental Health (NIMH) | 2 |
| Bristol-Myers Squibb | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for AIDS Dementia Complex? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Zidovudine | 5 |
| Selegiline | 2 |
| CPI-1189 | 2 |
| ATORVASTATIN | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ferumoxytol infusion | 2 |
| HAART | 1 |
| Galantamine ER | 1 |
| Insulin, intranasal | 1 |
| 11C-PBR28 | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do AIDS Dementia Complex trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Death | 2 | 2 |
| Gastrointestinal Bleeding | 2 | 1 |
| Major depressive episode | 2 | 1 |
| Bone fracture | 1 | 1 |
| Cardiac event | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover AIDS Dementia Complex? (105)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals. | AIDS (London, England) | 2018 | Yes |
| Medicalising normality? Using a simulated dataset to assess the performance of different diagnostic criteria of HIV-associated cognitive impairment. | PloS one | 2018 | Yes |
| A single low dose of hydrocortisone enhances cognitive functioning in HIV-infected women. | AIDS (London, England) | 2018 | Yes |
| Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients. | The Journal of antimicrobial chemotherapy | 2017 | Yes |
| Prevalence and Correlates of Probable HIV-Associated Dementia in HIV Outpatients in Ho Chi Minh City, Vietnam. | Journal of the International Association of Providers of AIDS Care | 2017 | Yes |
Showing 5 of 105 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.